OneSkin reverses skin biological age with targeted peptide
- OneSkin's OS-01 peptide reversed human skin biological age from 79 to 66 in lab models.
- Retinol accelerates cell turnover but elevates inflammatory biomarkers that exhaust skin stem cells.
- Four Brazilian PhDs grew 2,000 human tissue models to bypass flawed animal testing pipelines.
Retinol has a dirty secret. The cosmetic industry's gold standard forces rapid cell renewal, but it extracts a heavy cellular tax.
On Moonshots with Peter Diamandis, OneSkin CEO Carolina de Oliveira explained that topical retinoic acid upregulates p16, a biomarker directly tied to cellular senescence. Forcing rapid division on aging skin exhausts the stem cell niche. Over time, the process replaces compromised tissue with equally damaged new cells.
Senescent cells make up only 1% to 5% of skin tissue. Yet because skin is the body's largest organ, these zombie cells secrete inflammatory factors that degrade adjacent tissue and drive systemic chronic inflammation. De Oliveira suggested managing this localized breakdown could even mitigate systemic conditions like Alzheimer's.
To fix the flaw, de Oliveira and her team screened over 1,000 short peptides. They eventually isolated OS-01, a 10-amino-acid sequence small enough to cross the stratum corneum into the dermis. Rather than forcing cell division, OS-01 selectively clears zombie cells, reducing cellular senescence by 25% to 50% in laboratory testing.
The results in human models are stark. Using epigenetic DNA methylation clocks trained on more than 500 skin samples, OneSkin evaluated biological age in 3D tissue models reconstructed from donors aged 50 to 90. Treatment with OS-01 dropped biological age from 79 years down to 66 years in vitro without triggering inflammatory cascades.
The company built this dataset by abandoning traditional rodent testing. Co-founders de Oliveira and Chief Scientific Officer Alessandra Zonari grew more than 2,000 pieces of 3D human skin in vitro, combining disciplines across stem cell biology, bioinformatics, and tissue engineering. Skipping animal models eliminates the translational failures that usually derail biotech candidates moving to human trials.
OneSkin is moving from lab dishes to live human tissue. A ten-patient clinical trial will track biological age reversal in vivo using skin biopsies taken behind the ear over six to twelve months of daily application. At the same time, Zonari and the team are testing whether systemic delivery of OS-01 in animal models can lower cardiovascular risk and combat age-related cognitive decline.
Targeting cellular damage beats forcing premature division. Longevity science is finally moving past superficial trade-offs.
Source Intelligence
- Deep dive into what was said in the episodes
Michael Kratsios on the New Golden Age of American Science | EP #276 • Aug 4
- Carolina de Oliveira explains that senescent cells make up only 1% to 5% of skin tissue but drive systemic inflammation because the skin is the largest organ. Managing this localized inflammation could potentially mitigate systemic chronic diseases like Alzheimer's.
- Carolina de Oliveira explains that OneSkin screened an initial library of 200 antimicrobial peptides in collaboration with the Catholic University of Brasilia. Through iterative optimization of 800 additional peptides, they identified the 10-amino-acid peptide OS-01.
- Carolina de Oliveira states that the 10-amino-acid size of the OS-01 peptide allows it to successfully penetrate the skin barrier into the dermis. In laboratory testing, OS-01 reduced cellular senescence levels by 25% to 50%.
- Carolina de Oliveira claims that in vitro testing on 3D human skin models reconstructed from donors aged 50 to 90 years demonstrated biological age reversal. Specifically, treatment with OS-01 reversed the biological age of skin models from 79 to 66 years.
- Carolina de Oliveira explains that OneSkin developed a proprietary algorithm to measure skin biological age. The algorithm evaluates DNA methylation patterns and was trained using a dataset of over 500 distinct skin samples.
- Carolina de Oliveira argues that while retinol accelerates cell renewal, it simultaneously increases cellular inflammation and upregulates aging-related genes like p16. Overusing retinol risks exhausting local stem cell pools due to constant, non-selective cellular division.
- Carolina de Oliveira notes that OneSkin has grown and tested more than 2,000 human skin tissue samples in vitro to validate the safety and efficacy of the OS-01 peptide. This human-model approach yields higher clinical translation success than animal testing.
- Carolina de Oliveira outlines an upcoming clinical trial that will recruit 10 patients to use the topical formulation for six months to a year. Researchers will collect biopsies behind the ear to measure biological age reversal in vivo.
- Alexandra explains that because senescent cells play active, essential roles during different phases of wound healing, OS-01 is not recommended for active wounds. However, applying the peptide to established scar tissue may help by clearing the surrounding accumulation of senescent cells.
- Alexandra reveals that OneSkin is evaluating the systemic effects of the OS-01 peptide in animal models. The company is studying whether systemic delivery can reduce obesity-related inflammation, lower cardiovascular risk, and improve cognitive performance and memory in aged subjects.